Metformin Tied to Better Clinical Outcomes in CKD, CHF, CLD

Share this content:
Metformin Tied to Better Clinical Outcomes in CKD, CHF, CLD
Metformin Tied to Better Clinical Outcomes in CKD, CHF, CLD

WEDNESDAY, Jan. 4, 2017 (HealthDay News) -- For patients with chronic kidney disease (CKD), congestive heart failure (CHF), or chronic liver disease (CLD) with hepatic impairment, metformin use is associated with improvements in clinical outcomes, according to a review published online Jan. 3 in the Annals of Internal Medicine.

Matthew J. Crowley, M.D., from the Durham Veterans Affairs Medical Center and Duke University School of Medicine in North Carolina, and colleagues synthesized data addressing outcomes of metformin use in patients with type 2 diabetes and moderate to severe CKD, CHF, or CLD with hepatic impairment. Data were included from studies that compared diabetes regimens that included metformin with those that did not, and reported all-cause mortality, major adverse cardiovascular events, and other outcomes of interest.

The researchers found that metformin use correlated with reduced all-cause mortality in patients with CKD, CHF, or CLD with hepatic involvement on the basis of quantitative and qualitative syntheses involving 17 observational studies. In patients with CKD or CHF, metformin use correlated with fewer heart failure readmissions.

"Metformin use in patients with moderate CKD, CHF, or CLD with hepatic impairment is associated with improvements in key clinical outcomes," the authors write. "Our findings support the recent changes in metformin labeling."

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Incident Contrast Sensitivity Common in Middle-Aged Adults

Incident Contrast Sensitivity Common in Middle-Aged Adults

Factors linked to elevated risk include cadmium level in highest quintile, older age, more plaque sites

Tafamidis Treats Transthyretin Amyloid Cardiomyopathy

Tafamidis Treats Transthyretin Amyloid Cardiomyopathy

Reduces all-cause mortality, cardiovascular-related hospitalizations compared with placebo

Scribes Improve Physician Workflow, Patient Interaction

Scribes Improve Physician Workflow, Patient Interaction

Scribes lower EHR documentation burden for doctors and increase time spent interacting with patients

is free, fast, and customized just for you!




Already a member?

Sign In Now »